Clinical Trial Update: Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of S18986 in patients with mild cognitive impairment; the study has terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• S18986

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Mild Cognitive Impairment | Phase 2 | Status: TERMINATED